Home > 5,5-Diphenylhydantoin sodium salt > 5,5-Diphenylhydantoin sodium salt(630-93-3)
5,5-Diphenylhydantoin sodium salt(630-93-3)
Supplier Product Identification
Physical and Chemical Properties
First Aid Measures
Handling and Storage
Hazards Identification
Exposure Controls/Personal Protection
Fire Fighting Measures
Accidental Release Measures
Stability and Reactivity
Product Identification
Product Name
5,5-Diphenylhydantoin sodium salt
5,5-Diphenylhydantoin sodium salt
Synonyms
2,4-Imidazolidinedione, 5,5-diphenyl-, monosodium salt
5,5-Diphenyhydanthoin sodium
Lepitoin sodium
Minetoin
Sodium 5,5-diphenyl-2,4-imidazolidinedione
Sodium diphenylhydantoin
2,4-Imidazolidinedione, 5,5-diphenyl-, monosodium salt
5,5-Diphenyhydanthoin sodium
Lepitoin sodium
Minetoin
Sodium 5,5-diphenyl-2,4-imidazolidinedione
Sodium diphenylhydantoin
CAS
630-93-3
630-93-3
Formula
C15H12N2NaO2
C15H12N2NaO2
Molecular Weight
275.26
275.26
EINECS
211-148-2
211-148-2
RTECS
MU1400000
MU1400000
RTECS Class
Tumorigen; Drug; Mutagen; Reproductive Effector; Human Data
Tumorigen; Drug; Mutagen; Reproductive Effector; Human Data
Beilstein/Gmelin
4221969
4221969
Physical and Chemical Properties
Appearance
White powder.
White powder.
Solubility in water
Soluble.
Soluble.
Melting Point
292-299
292-299
pKa/pKb
8.06 (pKa)
8.06 (pKa)
Heat Of Vaporization
Usage
Medication (vet), recommended for epileptic seizures in dogs.
Medication (vet), recommended for epileptic seizures in dogs.
First Aid Measures
Ingestion
Seek medical attention. If individual is drowsy or unconscious, do not give anything by mouth; place individual on the left side with the head down. Contact a physician, medical facility, or poison control center for advice about whether to induce vomiting. If possible, do not leave individual unattended.
Seek medical attention. If individual is drowsy or unconscious, do not give anything by mouth; place individual on the left side with the head down. Contact a physician, medical facility, or poison control center for advice about whether to induce vomiting. If possible, do not leave individual unattended.
Inhalation
If symptoms develop, move individual away from exposure and into fresh air. If symptoms persist, seek medical attention. If breathing is difficult, administer oxygen. Keep person warm and quiet; seek immediate medical attention.
If symptoms develop, move individual away from exposure and into fresh air. If symptoms persist, seek medical attention. If breathing is difficult, administer oxygen. Keep person warm and quiet; seek immediate medical attention.
Skin
Flush skin with plenty of soap and water for at least 15 minutes while removing contaminated clothing and shoes.
Flush skin with plenty of soap and water for at least 15 minutes while removing contaminated clothing and shoes.
Eyes
If symptoms develop, immediately move individual away from exposure and into fresh air. Flush eyes gently with water for at least 15 minutes while holding eyelids apart; seek immediate medical attention.
If symptoms develop, immediately move individual away from exposure and into fresh air. Flush eyes gently with water for at least 15 minutes while holding eyelids apart; seek immediate medical attention.
Handling and Storage
Storage
Storage location should be close to laboratory where it is to be used, so that only small amounts need to be transported. Carcinogens should be kept in only one section of storage area, explosion-proof refrigerator or freezer as required. The area should be appropriately labeled. An inventory should be kept showing the quantity of carcinogen and date it was acquired. Facilities for dispensing should be contiguous to storage area. Chemical carcinogens store below 40C, preferably between 15 and 30C, unless otherwise specified by manufacturer. Store in a tight container. Protect from freezing.
Storage location should be close to laboratory where it is to be used, so that only small amounts need to be transported. Carcinogens should be kept in only one section of storage area, explosion-proof refrigerator or freezer as required. The area should be appropriately labeled. An inventory should be kept showing the quantity of carcinogen and date it was acquired. Facilities for dispensing should be contiguous to storage area. Chemical carcinogens store below 40C, preferably between 15 and 30C, unless otherwise specified by manufacturer. Store in a tight container. Protect from freezing.
Handling
Avoid contact. Only used in a chemical hood, while using protective equipment.
Avoid contact. Only used in a chemical hood, while using protective equipment.
Hazards Identification
Inhalation
Nausea, dizziness, headache, ataxia, blurred vision, nystagmus, and mental confusion.
Nausea, dizziness, headache, ataxia, blurred vision, nystagmus, and mental confusion.
Skin
Cutaneous eruptions following phenytoin therapy are common. Purple glove syndrome has been reported following intravenous phenytoin.
Cutaneous eruptions following phenytoin therapy are common. Purple glove syndrome has been reported following intravenous phenytoin.
Eyes
Irritation.
Irritation.
Ingestion
Harmful fi swallowed. Can cause gastrointestinal disturbances, nausea, slurred speach.
Harmful fi swallowed. Can cause gastrointestinal disturbances, nausea, slurred speach.
Exposure Controls/Personal Protection
Personal Protection
Dispensers of liquid detergent should be available. In the laboratory, gloves and protective clothing should always be worn but should not be assumed to provide full protection. Carefully fitted masks or respirators may be necessary when working with particulates or gases, and disposable plastic aprons might provide additional protection. Protective clothing should be of distinctive color, as a reminder not to be worn outside the laboratory.
Dispensers of liquid detergent should be available. In the laboratory, gloves and protective clothing should always be worn but should not be assumed to provide full protection. Carefully fitted masks or respirators may be necessary when working with particulates or gases, and disposable plastic aprons might provide additional protection. Protective clothing should be of distinctive color, as a reminder not to be worn outside the laboratory.
Respirators
NIOSH approved respirator.
NIOSH approved respirator.
Exposure Effects
Cerebellar ataxia, nystagmus, hyperreflexia, drowsiness, lethargy, and coma may occur. Choreoathetosis and dyskinesias have been reported. CNS depression may occur more commonly in children, and ataxia may occur more commonly in adults.
Cerebellar ataxia, nystagmus, hyperreflexia, drowsiness, lethargy, and coma may occur. Choreoathetosis and dyskinesias have been reported. CNS depression may occur more commonly in children, and ataxia may occur more commonly in adults.
Fire Fighting Measures
Fire Fighting
Wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion. Use agent most appropriate to extinguish fire.
Wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion. Use agent most appropriate to extinguish fire.
Accidental Release Measures
Small spills/leaks
Evacutae area. Wear approved SCBA, rubber boots and gloves. Sweep up and place in a bag for waste disposal. Avoid reaising dust. Ventilate area. Wash spill site after pickup is complete.
Evacutae area. Wear approved SCBA, rubber boots and gloves. Sweep up and place in a bag for waste disposal. Avoid reaising dust. Ventilate area. Wash spill site after pickup is complete.
Stability and Reactivity
Stability
Sensitive to light phenytoin a slight yellowing of the solution will not affect its potency. After being refrigerated, solution may form a precipitate which usually dissolves after being warmed to room temperature; however, do not use if the solution is not clear.
Sensitive to light phenytoin a slight yellowing of the solution will not affect its potency. After being refrigerated, solution may form a precipitate which usually dissolves after being warmed to room temperature; however, do not use if the solution is not clear.
Incompatibilities
Strong oxidizing agents.
Strong oxidizing agents.
Decomposition
Oxides of carbon and nitrogen.
Oxides of carbon and nitrogen.
Contact
More
- Company Name:Taishan Xinning Pharmaceutical Co., Ltd.
- Tel:0750-7171678
- Fax:
- WebSite:http://www.chinaxnp.com
- Company Name:J & K SCIENTIFIC LTD.
- Tel:010-82848833 400-666-7788
- Fax:86-10-82849933
- WebSite:http://www.jkchemical.com
- Company Name:Meryer (Shanghai) Chemical Technology Co., Ltd.
- Tel:021-61259108 18621169109
- Fax:86-21-61259102
- WebSite:https://www.meryer.com/cn/index/
- Company Name:3B Pharmachem (Wuhan) International Co.,Ltd.
- Tel:821-50328103-801 18930552037
- Fax:86-21-50328109
- WebSite:https://www.chemicalbook.com/ShowSupplierProductsList13285/0.htm
- Company Name:future industrial shanghai co., ltd
- Tel:400-0066400 13621662912
- Fax:021-55660885
- WebSite:http://www.jonln.com